Endo Inc.

OTCPK:ENDP.Q Stock Report

Market Cap: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Management

Management criteria checks 3/4

Endo International's CEO is Blaise Coleman, appointed in Dec 2016, has a tenure of 7.42 years. total yearly compensation is $12.85M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $253.23. The average tenure of the management team and the board of directors is 4.8 years and 7 years respectively.

Key information

Blaise Coleman

Chief executive officer

US$12.8m

Total compensation

CEO salary percentage7.6%
CEO tenure7.4yrs
CEO ownership0.2%
Management average tenure4.8yrs
Board average tenure7yrs

Recent management updates

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo International sees 23% rise on 3x higher than normal volume

Aug 03

Endo outperforms defying bankruptcy fears and generic entry

Jul 25

Endo weighs bankruptcy filing without opioid settlement - WSJ

Jul 12

Endo International cools off, giving back some of its 85% Tuesday gain

Jun 29

Endo: Stick A Fork In It

May 10

Endo: About As Bad As It Gets

Mar 07

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Dec 16

Endo: A Win In California But Equity Value Still A Question

Nov 02

Endo International: Loses Vasostrict Trial

Aug 31

Endo International: Hires Restructuring Advisor

Aug 20

Endo International: All About Ongoing Litigation

Aug 07

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

CEO Compensation Analysis

How has Blaise Coleman's remuneration changed compared to Endo International's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$2b

Sep 30 2023n/an/a

-US$252m

Jun 30 2023n/an/a

-US$942m

Mar 31 2023n/an/a

-US$3b

Dec 31 2022US$13mUS$978k

-US$3b

Sep 30 2022n/an/a

-US$3b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$681m

Dec 31 2021US$29mUS$913k

-US$569m

Sep 30 2021n/an/a

US$129m

Jun 30 2021n/an/a

US$109m

Mar 31 2021n/an/a

US$137m

Dec 31 2020US$7mUS$829k

US$247m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$75m

Mar 31 2020n/an/a

-US$190m

Dec 31 2019US$4mUS$612k

-US$361m

Sep 30 2019n/an/a

-US$418m

Jun 30 2019n/an/a

-US$522m

Mar 31 2019n/an/a

-US$477m

Dec 31 2018US$3mUS$569k

-US$962m

Sep 30 2018n/an/a

-US$968m

Jun 30 2018n/an/a

-US$921m

Mar 31 2018n/an/a

-US$2b

Dec 31 2017US$4mUS$546k

-US$1b

Compensation vs Market: Blaise's total compensation ($USD12.85M) is above average for companies of similar size in the US market ($USD674.46K).

Compensation vs Earnings: Blaise's compensation has been consistent with company performance over the past year.

CEO

Blaise Coleman (49 yo)

7.4yrs

Tenure

US$12,849,847

Compensation

Mr. Blaise A. Coleman serves as President, Chief Executive Officer and Director of Endo Inc. Mr. Blaise serves as President, Chief Executive Officer and Director at Endo International plc since March 06, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Blaise Coleman
President7.4yrsUS$12.85m0.18%
$ 253.2
Matthew Maletta
Executive VP9yrsUS$4.25m0.15%
$ 210.7
James Tursi
Executive Vice President of Global Research & Development2.3yrsUS$6.36mno data
Mark Bradley
Executive VP & CFO4.2yrsUS$7.98mno data
Frank Raciti
VP, Controller & Chief Accounting Officerno datano datano data
Cheryl Stouch
Senior VP of Information Technology & Chief Information Officer1.9yrsno datano data
Laure Park
Senior Vice President of Investor Relations & Corporate Affairs5.8yrsno datano data
Susan Williamson
Senior VP & Chief Compliance Officer6.1yrsno datano data
Tracy Basso
Chief Human Resources Officer4.8yrsno datano data
Patrick Barry
Executive VP & President of Global Commercial Operations7.4yrsUS$7.78mno data
James Papp
Head of Endo Ventures Limited & Senior VP of Global Supply Chain3.5yrsno datano data
Michael McGuinness
Global Head of Quality & Compliance1.9yrsno datano data

4.8yrs

Average Tenure

54yo

Average Age

Experienced Management: ENDP.Q's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Blaise Coleman
President4.2yrsUS$12.85m0.18%
$ 253.2
Mark Barberio
Independent Chairman4.3yrsUS$840.00k0.016%
$ 22.9
Michael Hyatt
Independent Director10.3yrsUS$625.00k0.15%
$ 213.3
William Montague
Independent Director10.3yrsUS$625.00k0.042%
$ 59.3
Shane Cooke
Independent Director9.8yrsUS$505.00k0.043%
$ 60.0
Jennifer Chao
Independent Director3.3yrsUS$480.00k0.011%
$ 14.9
Nancy Hutson
Independent Director10.3yrsUS$505.00k0.047%
$ 65.8
Mary Smith
Independent Non-Executive Director3.8yrsUS$480.00k0.014%
$ 19.7

7.0yrs

Average Tenure

61yo

Average Age

Experienced Board: ENDP.Q's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/02 11:05
End of Day Share Price 2024/05/02 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research